United Therapeutics Corporation $UTHR Stock Holdings Lifted by Employees Retirement System of Texas

Employees Retirement System of Texas lifted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 693.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,832 shares of the biotechnology company’s stock after buying an additional 2,475 shares during the quarter. Employees Retirement System of Texas’ holdings in United Therapeutics were worth $1,380,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Torren Management LLC bought a new stake in United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management lifted its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC bought a new stake in United Therapeutics in the 4th quarter valued at about $31,000. Wilmington Savings Fund Society FSB lifted its position in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new stake in United Therapeutics in the 4th quarter valued at about $48,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

UTHR stock opened at $570.75 on Thursday. The stock has a market cap of $24.23 billion, a P/E ratio of 21.07, a P/E/G ratio of 1.87 and a beta of 0.60. The firm has a 50 day simple moving average of $565.54 and a 200 day simple moving average of $514.75. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.63 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 27.07 EPS for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent research reports. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. HC Wainwright lifted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $619.42.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $562.82, for a total value of $4,671,406.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at $25,423,705.04. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 8,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $572.38, for a total transaction of $4,579,040.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $23,188,830.94. This trade represents a 16.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 581,973 shares of company stock worth $325,968,044 over the last ninety days. 8.60% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.